Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2024-02-15 00:00:00 ET · period of report 2024-02-13 · accession 0000914475-24-000076 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-15 | 2024-02-13 | NBIX | ROBERTS EIRY | Chief Medical Off | S - Sale | $132.96 | -1,114 | 23.7K | -4% | -$148.1K |
| DM | 2024-02-15 | 2024-02-13 | NBIX | ROBERTS EIRY | Chief Medical Off | A - Grant | $0.00 | +27.0K | 22.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-13 | S | D | 1,114 | $132.96 | 23,716 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F3) 18,336 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. |
| 2 | Derivative | Restricted Stock Unit | 2024-02-13 | A | A | 4,483 | $0.00 | 4,483 | D | — · — to — | 4,483 Common Stock | (F5) Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. (F6) The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. |
| 3 | Derivative | Stock Option | 2024-02-13 | A | A | 22,529 | $0.00 | 22,529 | D | $133.84 · — to 2034-02-13 | 22,529 Common Stock | (F4) Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |